Gain Therapeutics

GANX

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding

In their latest 13F (Q3 2026)

See who

Value held

$1.1m

Combined value at quarter end

Last quarter

0 bought

0 sold or trimmed

Price at Q2 ’26 end

$2.03

+4.6% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+39.1%Q3 ’24

+21.3%Q4 ’24

-11.6%Q1 ’25

-5.8%Q2 ’25

-1.7%Q3 ’25

+81.9%Q4 ’25

-39.8%Q1 ’26

+4.6%Q2 ’26

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

1Q4 ’23

1Q1 ’24

1Q2 ’24

1Q3 ’24

1Q4 ’24

1Q1 ’25

1Q2 ’25

1Q3 ’25

1Q4 ’25

1Q1 ’26

1Q2 ’26

0Q3 ’26

Counts the managers on this site whose 13F for that quarter includes Gain Therapeutics.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Gain Therapeutics

Greenlight Capital	0.0%$1.1m	$1.1m	Unchanged	22 qtrs

Download the holders: CSV · JSON · Markdown

About the company

Sector: Health care · Pharmaceutical Preparations
Incorporated in: Delaware
Financial year ends: 31 December
Shares outstanding: 44m at 31 Jul 2026
SEC filings: Annual reports and other filings on EDGAR

Revenue and profit

$29k2020

$165k2021

$140k2022

$55k2023

2024

2025

Gain Therapeutics revenue and net income by year
Year	Revenue	Net income
2025	–	−$20.2m
2024	–	−$20.4m
2023	$55k	−$22.3m
2022	$140k	−$17.6m
2021	$165k	−$13.9m
2020	$29k	−$3.6m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.